A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

التفاصيل البيبلوغرافية
العنوان: A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
المؤلفون: Matthew D. Snape, Natalie G Martin
المصدر: Expert Review of Vaccines. 12:837-858
بيانات النشر: Informa UK Limited, 2013.
سنة النشر: 2013
مصطلحات موضوعية: Drug-Related Side Effects and Adverse Reactions, Fever, Immunology, Meningococcal Vaccines, Meningococcal vaccine, Neisseria meningitidis, Serogroup B, medicine.disease_cause, Drug Discovery, Drug approval, Humans, Medicine, Drug Approval, Immunization Schedule, Pharmacology, High rate, Reactogenicity, business.industry, Neisseria meningitidis, Immunogenicity, Virology, Europe, Meningococcal Infections, Clinical trial, Immunization, Molecular Medicine, business
الوصف: The first meningococcal vaccine with the potential to provide broad coverage against serogroup B disease has recently been approved for use in Europe. This vaccine, multi-component serogroup B vaccine (4CMenB), contains recombinant proteins and outer membrane vesicles, and has been extensively studied in clinical trials involving over 7500 adults, children and infants. As well as demonstrating immunogenicity against a range of serogroup B meningococcal strains, these trials have also demonstrated relatively high rates of fever following infant immunization. This article will summarize the vaccine composition, clinical trials and suggested schedules of this vaccine, with specific attention to immunogenicity, reactogenicity, safety, potential coverage and optimal implementation of this vaccine.
تدمد: 1744-8395
1476-0584
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65b5547c1dca6cb286f8cdb8f9ee1508Test
https://doi.org/10.1586/14760584.2013.814862Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....65b5547c1dca6cb286f8cdb8f9ee1508
قاعدة البيانات: OpenAIRE